AKTX vs PHAR
Akari Therapeutics, Plc · Pharming Group N.V.
Relative return (rebased to 100)
Key stats
| Metric | AKTX | PHAR |
|---|---|---|
| Price | $7.00 | $10.95 |
| Market Cap | $640.97B | $7.68B |
| P/E | — | 2694.98 |
| P/B | 44573.65 | 27.73 |
| P/S | 1742346.13 | 20.43 |
| ROE | -120.3% | 1.0% |
| Net Margin | -4702.1% | 0.8% |
| Gross Margin | — | 87.9% |
| Revenue Growth | -39.5% | 26.6% |
| Dividend Yield | — | — |
| EPS | -$0.00 | $0.00 |
Metrics from owned fundamentals, updated daily. Highlighted values are the more favorable of the two.